Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: Mixed κ agonists and μ agonists/antagonists as potential pharmacotherapeutics for cocaine dependence

Journal of Medicinal Chemistry

Volumn 43, Issue 1, 2000, Pages 114-122

  Neumeyer, John L ^a   Bidlack, Jean M ^b   Zong, Rushi ^a   Bakthavachalam, Venkatesalu ^c   Gao, Peng ^c   Cohen, Dana J ^b   Negus, S Stevens ^a   Mello, Nancy K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c Research Biochemicals International   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY N (TETRAHYDROFURFURYL)MORPHINAN; 3 HYDROXY N CYCLOBUTYLMETHYLMORPHINAN MANDELIC ACID; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; BENZOMORPHAN DERIVATIVE; CYCLAZOCINE; CYCLORPHAN; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; ETHYLKETAZOCINE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; MORPHINAN DERIVATIVE; MORPHINE SULFATE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR ANTAGONIST; N,N DIALLYLTYROSYL 2 METHYLALANYL 2 METHYLALANYLPHENYLALANYLLEUCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; BINDING AFFINITY; COCAINE DEPENDENCE; DRUG ABUSE; DRUG DEPENDENCE TREATMENT; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; MOUSE; NONHUMAN;

ACETIC ACID; ANIMALS; BENZOMORPHANS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHYLKETOCYCLAZOCINE; GUINEA PIGS; INJECTIONS, INTRAVENTRICULAR; MALE; MICE; MICE, INBRED ICR; MORPHINANS; MORPHINE; NARCOTIC ANTAGONISTS; PAIN; PAIN MEASUREMENT; REACTION TIME; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU;

EID: 0034642516     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9903343     Document Type: Article

References (45)

1. Martin, W. R.; Eades, C. G.; Thompson, J. A.; Huppler, R. E.; Gilbert, P. E. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent dog. J. Pharmacol. Exp. Ther. 1976, 197, 517-532.
2. Mansour, A.; Khachaturian, H.; Lewis, M. E.; Akil, H.; Watson, S. J. Autoradiographic differentiation of mu, delta and kappa opioid receptors in rat forebrain and midbrain. J. Neurosci. 1987, 7, 2445-2464.
3. Mansour, A.; Khachaturian, H.; Lewis, M. E.; Akil, H.; Watson, S. J. Anatomy of CNS opioid receptors. Trends Neurosci. 1988, 11, 308-314.
4. Mansour, A.; Fox, C. A.; Burke, S.; Meng, F.; Thompson, R. C.; Akil, H.; Watson, S. J. Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: An in situ hybridization study. J. Comp. Neurol. 1994, 350, 412-438.
5. Hokfelt, T.; Vincent, S. R.; Dalsgaard, C. J.; Herrera-Marschitz, M.; Understedt, U.; Schultzberg, M.; Christensson, I.; Terenius, L. Some aspects on distribution and role of opioid peptides in the central and peripheral nervous system. In Central and Peripheral Endorphins: Basic and Clinical Aspects; Muller, E. E., Genazzani, A. R., Eds.; Raven Press: New York, 1984; pp 1-16.
6. Chavkin, C.; James, I. F.; Goldstein, A. Dynorphin is a specific endogenous ligand of the κ opioid receptor. Science 1982, 215, 413-415.
7. Devine, D. P.; Leone, P.; Pocock, D.; Wise, R. A. Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: In vivo microdialysis studies. J. Pharamcol. Exp. Ther. 1993, 266, 1236-1246.
8. DiChiara, G.; Imperato, A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 5274-5278.
9. Spanagel, R.; Herz, A.; Shippenberg, T. S. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway, Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 2046-2050.
10. Maisonneuve, I. M.; Archer, S.; Click, S. D. U50.488 a K opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci. Lett. 1994, 181, 57-60.
11. Crawford, C. A.; McDougall, S. A.; Bolanos, C. A.; Hall, S.; Berger, S. P. The effects of the kappa agonist U-50,488 on cocaine-induced conditioned and unconditioned behaviors and Fos immunoreactivity. Psychopharmacology 1995, 120, 392-399.
12. Ukai, M.; Mizutani, M.; Kameyama, T. Opioid peptides selective for receptor types modulate cocaine-induced behavioral responses in mice. Yakubutsu Seishin Kodo 1994, 14, 153-159.
13. Shippenberg, T. S.; LeFevour, A.; Heidbreder, C. H. κ-Opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine. J. Pharmacol. Exp. Ther. 1996, 276, 545-554.
14. Suzuki, T.; Shiozaki, Y.; Masukawa, Y.; Misawa, M.; Nagase, H. The role of mu- and kappa-opioid receptors in cocaine-induced conditioned place preference. Jpn. J. Pharmacol. 1992, 58, 435-442.
15. Spealman, R. D.; Bergman, J. Modulation of the discriminative-stimulus effects of cocaine by mu and kappa opioids. J. Pharmacol. Exp. Ther. 1992, 261, 607-615.
16. Spealman, R. D.; Bergman, J. Opioid modulation of the discriminative stimulus effects of cocaine: Comparison of μ, κ and ∂ agonists in squirrel monkeys discriminating low doses of cocaine. Behav. Pharmacol. 1994, 5, 21-31.
17. Archer, S.; Glick, S. D.; Bidlack, J. M. Cyclazocine revisited. Neurochem. Res. 1996, 21, 1369-1373.
18. Negus, S. S.; Mello, N. K.; Portoghese, P. S.; Lin, C.-E. Effects of kappa opioids on cocaine self-administration by rhesus monkeys. J. Pharmacol. Exp. Ther. 1997, 282, 44-55.
19. Mello, N. K.; Negus, S. S. Effects of kappa opioid agonists on cocaine- and food-maintained responding by rhesus monkeys. J. Pharmacol. Exp. Ther. 1998, 286, 812-824.
20. Gates, M.; Montzka, T. A. Some morphine antagonists possessing high analgesic activity. J. Med. Chem. 1964, 7, 127-131.
21. Mertz, H.; Stockhaus, K.; Wick, H. Diastereoisomeric N-tetrahydro-furfuryloxy morphiines with opioid agonist-antagonist properties. J. Med. Chem. 1977, 20, 844-846.
22. Michne, W. F.; Albertson, N. F. Analgesic 1-oxidized-2,6-methano-3-benzazocines. J. Med. Chem. 1972, 15, 1278-1281.
23. Merz, H.; Stockhaus, K. N-[(Tetrahydrofurfuryl)alkyl] and N-(alkoxyalkyl) derivatives of (-)-normetazocine, compounds with differential opioid action profiles. J. Med. Chem. 1979, 22, 1475-1483.
24. Tullar, B. F.; Harris, L. S.; Perry, R. L.; Pierson, A. K.; Soria, A. E.; Wetterau, W. F.; Albertson, N. F. Benzomorphans: Optically active trans isomers. J. Med. Chem. 1967, 10, 383.
25. 6]enkephalin in the mouse. J. Pharmacol. Exp. Ther. 1987, 241, 393-400.
26. Magnan, J.; Paterson, S. J.; Tavani, A.; Kosterlitz, H. W. The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties. Naunyn-Schmiedeberg's Arch. Pharmacol. 1982, 319, 197-205.
27. Hein, D. W.; Young, A. M.; Herling, S.; Woods, J. H. Pharmacological analysis of the discriminative stimulus characteristics of ethylkotazocine in the rhesus monkey. J. Pharmacol. Exp. Ther. 1981, 218, 7-15.
28. Herling, S.; Hein, D. W.; Nemeth, M. A.; Valentine, R. J.; Woods, J. H. Discriminative stimulus effects, antagonist, and rate-decreasing effects of cyclorphan: Multiple modes of action. Life Sci. 1982, 30, 331-341.
29. Bertalmio, A. J.; Woods, J. H. Discriminative stimulus effects of cyclorphan: Selective antagonism with naltrexone. Psychopharmacology 1992, 106, 189-194.
30. Picker, M. J.; Yarbrough, J.; Hughes, C. E.; Smith, M. A.; Morgan, D.; Dykstra, L. A. Agonist and antagonist effects of mixed action opioids in the pigeon drug discrimination procedure: Influence of training dose, intrinsic efficacy and interanimal differences. J. Pharmacol. Exp. Ther. 1993, 266, 756-767.
31. Pachter, I. H. Synthetic 14-hydroxymorphinans. In Narcotic Antagonists: Advances in Biochemical Psychopharmacology. Vol 8; Braude, M. C., Harris, L. S., May, E. L., Smith, J. P., Villarreal, J. E., Eds.; Raven Press: New York, 1973; pp 57-62.
32. Blumberg, H.; Dayton, H. B. Naloxone, naltrexone, and related noroxymorphones. In Narcotic Antagonists: Advances in Biochemical Psychopharmacology. Vol. 8; Braude, M. C., Harris, L. S., May, E. L., Smith, J. P., Villarreal, J. E., Eds.; Raven Press: New York, 1973; pp 33-43.
33. Clarke, F. H.; Hill, R. T.; Saelens, J. K.; Yokoyama, N. Antagonsits in the 5-phenyl benzomorphan series. In Narcotic Antagonists: Advances in Biochemical Psychopharmacology. Vol. 8; Braude, M. C., Harris, L. S., May, E. L., Smith, J. P., Villarreal, J. E., Eds.; Raven Press: New York, 1973; pp 81-89.
34. Wood, P. L.; Charleson, S. E.; Lane, D.; Hudgin, R. L. Multiple opiate receptors: Differential binding of μ, κ and ∂ agonists. Neuropharmacology 1981, 20, 1215-1220.
35. Corrodi, H.; Hellenbach, J.; Zust, A.; Hardegger, E.; Schneider, O. Hydroxy-morphinane-Die Konfiguration des Morphinane. Helv. Chim. Acta 1959, 42, 212-214.
36. Olfoson, R. A.; Marts, J. T.; Seret, J. P.; Piteau, M.; Malfroot, T. A. A new reagent for the selective, high yield N-dealkylation of tertrary amines: Improved synthesis of naltrexone and albuphine. J. Org. Chem. 1984, 49, 2081-2082.
37. Abdel-Monem, M. M.; Portoghese, P. S. N-Demethylation of morphine and structurally related compounds with chloroformate esters. J. Med. Chem. 1972, 15, 210.
38. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the priniciple of protein-dye binding. J. Org. Chem. 1976, 47, 248-254.
39. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
40. Haley, T. J.; McCormick, W. G. Pharmacological effects produced by intracerebral injections of drugs in the conscious mouse. Br. J. Pharmacol. Chemother. 1957, 12, 12-15.
41. McLaughlin, J. P.; Hill, K. P.; Jiang, Q.; Sebastian, A.; Archer, S.; Bidlack, J. M. Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: In vivo and in vitro characterization of μ-selective agonist and antagonist activity. J. Pharmacol. Exp. Ther. 1999, 289, 304-311.
42. Vaught, J. L.; Takemori, A. E. Differential effects of leucine and methionine enkephalin on morphine-induced analgesia, acute tolerance and dependence. J. Pharmacol. Exp. Ther. 1979, 208, 86-90.
43. Xu, J. Y.; Seyed-Mozaffari, A.; Archer, S.; Bidlack, J. M. N-Cyclobutylmethyl analogue of normorphinone, N-CBM-TA-MO: A short-term opioid agonist and long-term mu-selective irreversible opioid antagonist. J. Pharmacol. Exp. Ther. 1996, 279, 539-547.
44. Munson, P. J.; Rodbard, D. LIGAND: A versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 1980, 107, 220-230.
45. Tallarida, R. J.; Murray, R. B. Manual of Pharmacologic Calculations with Computer Programs, 2nd ed.; Springer-Verlag: New York, 1986.